Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2013

View Archived Issues

Data reported from first trial of Thalagen gene therapy for beta-thalassemia

Resverlogix completes enrollment in phase II trial of RVX-208

Sucampo Pharmaceuticals reports data from ion channel activator study

Phase IIa study of Santarus' SAN-300 in rheumatoid arthritis begins

Constellation Pharmaceuticals synthesizes new bromodomain inhibitors

Primary endpoints achieved in two phase III trials of rolapitant

Vertex Pharmaceuticals designs novel agents for influenza

Characterization of a novel Abeta inhibitor for the treatment of Alzheimer's disease

Antisense Therapeutics reports data from interim analysis of ATL-1103

RedHill Biopharma reports promising data for RHB-105

Can-Fite BioPharma reports topline results from phase IIb study of CF-101

Kissei grants Pfizer development and commercialization rights for KUX-1151

Researchers from Fusion Pharma present a novel pan-BCR/ABL inhibitor, PF-114

Chinese herbal medicine demonstrates safety and efficacy in first U.S. trial in liver fibrosis

Researchers agree to repurpose experimental asthma drug for the treatment of cancer

Immune Response BioPharma announces development of a novel HIV/AIDS vaccine

Gilead Sciences and Selcia patent novel cyclophilin A inhibitors

Secukinumab filed in Japan by Novartis for psoriasis

Novartis presents additional clinical data for serelaxin

FDA extends action date for vedolizumab for ulcerative colitis

Takeda stops development of fasiglifam

Takeda submits NDA for fomepizole in Japan

Swedish Orphan Biovitrum temporarily withdraws NDA for Orfadin

IGFBP-7 serum levels correlate with clinical severity in patients with heart failure

Genzyme receives complete response letter for Lemtrada for relapsing MS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...